On November 27, 2020, China Grand Pharmaceutical and Healthcare Holdings Limited (Grand Pharma) won the award of "The Most Growing High-tech Listed Company" on the 9th Chinese Listed Companies Summit held by National Business Daily, relying on its remarkable achievements in the field of high-tech and high-barrier innovative drugs. Moreover, Grand Pharma is the only technological innovation-oriented pharmaceutical enterprise winning the award.
Chinese Listed Companies Summit is one of the most influential high-end economic summits in China. More than 300 excellent listed companies, high growth companies, and securities fund institutions, and even top economists and well-known investors at home and abroad were invited to the summit. Focusing on hot topics such as China's economic growth opportunities under the dual circulation, the planning of various fields in China during the 14th Five-Year Plan period, improving the adaptability of the supply system to domestic demand, high-level opening-up, big health and public health, and building a high ground for technology and innovation from a new development perspective, they thought deeply, judged prospectively and analyzed the endogenous dynamic of China's economy to determine the road of high-quality development of China's economy.
Technical innovation of the health industry is the core element of long-term value growth. The upgrading of products and industries by relying on technology empowerment has become the industry consensus. In recent years, Grand Pharma has got a keen insight into the future global innovation and development trend and made a forward-looking layout, especially making a detailed layout in "radionuclide–drug conjugate (RDC)", "precise interventional diagnosis and treatment" and "antiviral and anti-infection field".
The ability to select and invest in global innovative products, the strong ability to expand precisely domestic and foreign business, and the ability to introduce, digest and implement international leading technologies are the core competitiveness of Grand Pharma. As a pioneer in the layout of technical innovation, Grand Pharma will continue to deepen the strategy of "global operation layout and dual circulation operation and development", and actively look for high-quality partners and increase innovation projects at home and abroad to benefit patients. To give back to the market for its long-term support to our company, we are committed to becoming a technological innovation-oriented international pharmaceutical enterprise recognized and respected by patients and doctors.
SIR-Spheres® Yttrium-90 Microspheres Injections Introduced by Grandpharma Officially Launched in Chinese Market
Yuanda Shuyang's New Production Base for Blood Products Officially Put into Operation
Grand Opening of Chengdu Grand Shopping Center Forging a "New Epicenter on the axis of the City of Paradise”
China Grand Pharmaceutical's Revolutionary Medical Device Debut at CIIE
Live: China Grand’s Platinum Sale at the Nangang Store in the Shopping Center Break the convention and stick to our original creed
Huadong Medicine Ellansé’s Official Launch in China Met with Wide Acclaim by Authorities in the Medical Beauty Industry